• Steven E Schutzer, Tao Liu, Chia-Feng Tsai, Vladislav A Petyuk, Athena A Schepmoes, Yi-Ting Wang, Karl K Weitz, Jonas Bergquist, Richard D Smith, and Benjamin H Natelson.
• Department of Medicine, Rutgers NJ Medical School, Newark, NJ, USA.
• Ann. Med. 2023 Dec 1; 55 (1): 22083722208372.

BackgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and fibromyalgia have overlapping neurologic symptoms particularly disabling fatigue. This has given rise to the question whether they are distinct central nervous system (CNS) entities or is one an extension of the other.Material And MethodsTo investigate this, we used unbiased quantitative mass spectrometry-based proteomics to examine the most proximal fluid to the brain, cerebrospinal fluid (CSF). This was to ascertain if the proteome profile of one was the same or different from the other. We examined two separate groups of ME/CFS, one with (n = 15) and one without (n = 15) fibromyalgia.ResultsWe quantified a total of 2083 proteins using immunoaffinity depletion, tandem mass tag isobaric labelling and offline two-dimensional liquid chromatography coupled to tandem mass spectrometry, including 1789 that were quantified in all the CSF samples. ANOVA analysis did not yield any proteins with an adjusted p value <.05.ConclusionThis supports the notion that ME/CFS and fibromyalgia as currently defined are not distinct entities.Key messageME/CFS and fibromyalgia as currently defined are not distinct entities.Unbiased quantitative mass spectrometry-based proteomics can be used to discover cerebrospinal fluid proteins that are biomarkers for a condition such as we are studying.

11 keywords...

hide…